Transaction #24767 · Form 4 · 0001205903-26-000013
Iambic Therapeutics, Inc. · Conversion · Common Stock
Iambic Therapeutics, Inc. · Transacted October 16, 2026 · Filed October 19, 2026
What does this filing report?
An SEC Form 4 filing for Iambic Therapeutics, Inc. records a conversion involving Common Stock on October 16, 2026. The reported quantity was 8,341. The filing date is October 19, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Iambic Therapeutics, Inc.
- Company CIK
- 0001997038
- Security type
- Non-derivative
- Acquisition type
- Conversion · Code C
- Quantity acquired
- 8,341
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 200,920
- Ownership description
- See footnote
- SEC acceptance time
- Oct 19, 2026, 7:49 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- RASTETTER WILLIAM H ↗
Director · Chairperson of the Board
CIK 0001205903
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
- F2
- Each share of Series B-2 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
- F3
- Each share of Series B-3 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
- F4
- Each share of Series B-4 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
- F5
- The shares are held of record by the Rastetter Family Trust dated September 2, 2010, for which Dr. Rastetter serves as a trustee.
- F6
- The conversion price was equal to 85% of the Issuer's initial public offering price of $16.00 per share (reflecting a 15% discount).
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.